Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: feladilimab, medi-570, rozibafusp alfa +1 | 0.81 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 3 Parkinson's papers of 2,864 | 0.82 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 12782
Sealed predictions
- ICOS in dopamine neurons, braak-0.10 (p 0.795) → +0.32 (p 0.400)receipt 12788
Swarm cases
receipt 12788: ICOS in dopamine neurons, braak
- power
- full sample +0.13 (p 0.615, n 18), 95% CI -0.36 to +0.56. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.11 (p 0.658, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.16 (p 0.521, n 18). could be the mix.
- skeptic
- leave-one-out range -0.00 to +0.27, sign flips 1; without severely affected donors +0.13 (p 0.615, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ICOS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts